+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Crohn's Disease Therapeutics Market - Global Forecast to 2030- Product Image
Crohn's Disease Therapeutics Market - Global Forecast to 2030- Product Image
Sale

Crohn's Disease Therapeutics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014389
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Crohn's Disease Therapeutics Market grew from USD 13.36 billion in 2024 to USD 14.13 billion in 2025. It is expected to continue growing at a CAGR of 5.62%, reaching USD 18.55 billion by 2030.

Crohn’s disease represents a multifaceted challenge characterized by chronic inflammation of the gastrointestinal tract, unpredictable flares, and a substantial burden on patient quality of life. Advances in immunology, molecular biology, and patient monitoring have converged to reshape the therapeutic landscape, creating opportunities for more targeted, effective interventions. As healthcare systems worldwide grapple with cost containment, shifting reimbursement models, and evolving regulatory frameworks, stakeholders require a holistic understanding of emerging treatment paradigms, access considerations, and competitive dynamics. This executive summary distills critical insights into transformative shifts, policy impacts, segmentation analyses, regional variations, and key players shaping the Crohn’s disease arena, equipping decision-makers with the strategic perspective needed to navigate a complex environment and drive meaningful patient outcomes.

Transformative Shifts in the Therapeutic Landscape

Over the past decade, the Crohn’s disease ecosystem has undergone a dramatic metamorphosis propelled by breakthroughs in biologics, the maturation of small-molecule pipelines, and an intensified focus on personalized care. First, the rise of next-generation biologics-ranging from integrin antagonists to interleukin inhibitors-has expanded options for patients who previously exhibited primary or secondary nonresponse to conventional therapies. Simultaneously, accelerated regulatory pathways have facilitated earlier market entry for promising candidates, fostering a competitive environment that rewards innovation.

Alongside novel therapies, real-world evidence platforms and digital health tools are reshaping disease monitoring and adherence. Wearable sensors, patient-reported outcome apps, and telemedicine consultations have transitioned from pilot projects to integral components of comprehensive care models. These patient-centric initiatives not only enhance satisfaction but also generate robust datasets to inform iterative improvements in clinical protocols.

Finally, the growing emphasis on combination regimens-pairing biologics with immunomodulators or repurposed small molecules-highlights a strategic pivot toward multi-modal suppression of inflammation. This integrative approach addresses the heterogeneous nature of Crohn’s disease, paving the way for more nuanced treatment algorithms and improved long-term remission rates.

Cumulative Impact of United States Tariffs 2025

The introduction of new tariffs in 2025 has introduced both challenges and strategic imperatives for market participants. Import duties on active pharmaceutical ingredients and finished formulations have increased production costs, compelling manufacturers to revisit sourcing strategies. In response, several organizations have localized manufacturing operations closer to end markets or negotiated long-term supply agreements to mitigate price volatility.

Moreover, higher import levies have intensified discussions around value-based contracting and outcome-based reimbursements. Payers are scrutinizing cost-effectiveness data more rigorously, prompting manufacturers to provide real-world evidence of clinical benefit and health economic value. As a result, evidence generation is shifting upstream, with companies investing earlier in health outcomes studies to support formulary access.

On the distribution front, wholesalers and specialty pharmacies are adapting logistics networks to optimize duty-exempt corridors and leverage free trade zones. This operational realignment not only buffers the impact of tariffs but also enhances supply chain resilience amid global uncertainties. Collectively, these adaptive strategies underscore the sector’s agility in preserving patient access while navigating evolving trade policies.

Key Segmentation Insights

Analysis across therapeutic class reveals that anti-inflammatories and corticosteroids maintain steady utility, while biologics-subdivided into integrin antagonists, interleukin inhibitors, and tumor necrosis factor inhibitors-drive differentiated efficacy for moderate to severe cases and command premium positioning. When examining route of administration, injectable therapies delivered intravenously or subcutaneously are gaining uptake for their rapid onset of action, even as oral formulations offer patient convenience. On the dimension of drug type, biologics lead innovation pipelines, but small molecules retain strategic importance for maintenance stages and cost management. Age group segmentation highlights adults as the primary patient base, with geriatric and pediatric cohorts emerging as areas for tailored clinical research. Disease severity assessments show that moderate and severe presentations demand advanced therapies, whereas mild cases often rely on conventional anti-inflammatories. Prescription type analysis delineates prescription-only drugs as the mainstay, alongside burgeoning interest in over-the-counter adjuncts. Distribution channels span hospital pharmacies, online platforms, and retail outlets, each optimized for distinct patient journeys. Research and development activities balance biological studies-including clinical and preclinical trials-with chemical synthesis and drug repurposing efforts. Patient demographics, segmented by gender, lifestyle, and socioeconomic status, underscore disparities in access and adherence. End-user segmentation covers academic and research institutions, emergency services, and specialty clinics, reflecting diverse points of care. Treatment stage considerations distinguish initial therapy protocols from long-term maintenance, while technology adoption levels categorize markets by high, moderate, or low innovation readiness.

Key Regional Insights

In the Americas, robust healthcare infrastructure, favorable reimbursement frameworks, and expansive specialty pharmacy networks underpin broad access to both branded biologics and emerging small-molecule therapies. By contrast, Europe, Middle East & Africa exhibits marked heterogeneity: Western European markets prioritize health technology assessments and negotiated pricing; Eastern and Middle Eastern regions vary in regulatory agility and local manufacturing capacity; and African markets often face infrastructural and funding constraints that impede widespread uptake. Meanwhile, Asia-Pacific presents a dynamic mosaic, where developed markets such as Japan and Australia favor innovative therapies under strict regulatory oversight, while emerging economies in Southeast Asia and South Asia balance cost pressures with growing demand for advanced treatment options. Across all regions, cross-border collaborations and localized value-based care models are accelerating adoption curves and fostering more equitable patient outcomes.

Key Company Dynamics and Competitive Landscape

The competitive landscape features a blend of pharmaceutical titans and specialized biotechs. AbbVie Inc. and Amgen Inc. continue to refine their immunomodulatory portfolios, while Biogen Inc. explores novel targets informed by neuroscience-driven inflammation research. Bristol-Myers Squibb Company and Celgene Corporation chart combination strategies that leverage synergies between small molecules and monoclonal antibodies. Eli Lilly and Company and Ferring Pharmaceuticals Inc. invest in next-generation formulations and patient adherence technologies. Gilead Sciences Inc. and Ipsen Biopharmaceuticals, Inc. extend their global reach through partnerships with local distributors, whereas Johnson & Johnson and Merck & Co., Inc. emphasize integrated care pathways and real-world evidence generation. Nestlé Health Science advances adjunct nutritional therapies, complementing Novartis AG and Pfizer Inc.’s focus on precision medicine. Roche Holding AG and Sanofi S.A. maintain expansive clinical pipelines, supported by Shire plc. and Takeda Pharmaceutical Company Limited’s expertise in gastrointestinal disorders. Finally, Teva Pharmaceutical Industries Ltd. and UCB S.A. leverage generic and biosimilar strategies to address cost sensitivities, ensuring broad patient access across diverse markets.

Actionable Recommendations for Industry Leaders

Industry leaders should allocate R&D budgets toward precision biologics that target specific inflammatory pathways while concurrently advancing small-molecule candidates to serve maintenance and mild disease segments. Strengthening supply chain resilience through dual sourcing agreements and near-shoring initiatives will buffer against tariff-driven cost spikes and geopolitical risks. Investing in digital health solutions-from telemonitoring platforms to AI-driven adherence tools-can enhance patient engagement and generate valuable real-world outcomes data to support value-based contracts. Strategic alliances with payers and health systems will facilitate shared-risk agreements, aligning pricing models with demonstrable clinical benefits. Finally, embracing adaptive trial designs and collaborative networks with academic institutions will accelerate proof-of-concept studies and reduce time-to-market for high-potential candidates.

Conclusion and Strategic Imperatives

As Crohn’s disease therapeutics evolve, stakeholders must navigate a landscape defined by scientific innovation, regulatory complexity, and shifting reimbursement paradigms. Success will hinge on an integrated approach that combines advanced biologics with strategic small-molecule development, underpinned by a robust supply chain and enriched by digital health data. By aligning R&D investments with patient needs and payer expectations, companies can drive sustainable growth while delivering superior clinical outcomes. Collaboration across sectors-pharma, payers, providers, and technology partners-will unlock synergies that accelerate access and improve quality of life for patients worldwide.

Market Segmentation & Coverage

This research report categorizes the Crohn's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Anti-Inflammatories
  • Biologics
    • Integrin Antagonists
    • Interleukin Inhibitors
    • Tumor Necrosis Factor Inhibitors
  • Corticosteroids
  • Immunomodulators
  • Injectable
    • Intravenous
    • Subcutaneous
  • Oral
  • Topical
  • Biologics
  • Small Molecule
  • Adult
  • Geriatric
  • Pediatric
  • Mild
  • Moderate
  • Severe
  • Over-The-Counter (OTC)
  • Prescription Drugs
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Biological Studies
    • Clinical Trials
    • Preclinical Trials
  • Chemical Synthesis
  • Drug Repurposing
  • Gender
  • Lifestyle Factors
  • Socioeconomic Status
  • Academic and Research Institutions
  • Emergency Services
  • Specialty Clinics
  • Initial Therapy
  • Maintenance Therapy
  • High Innovation
  • Low Innovation
  • Moderate Innovation

This research report categorizes the Crohn's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Crohn's Disease Therapeutics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Ferring Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Nestlé Health Science
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Shire plc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Crohn's Disease Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Anti-Inflammatories
8.3. Biologics
8.3.1. Integrin Antagonists
8.3.2. Interleukin Inhibitors
8.3.3. Tumor Necrosis Factor Inhibitors
8.4. Corticosteroids
8.5. Immunomodulators
9. Crohn's Disease Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Oral
9.4. Topical
10. Crohn's Disease Therapeutics Market, by Drug Type
10.1. Introduction
10.2. Biologics
10.3. Small Molecule
11. Crohn's Disease Therapeutics Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Crohn's Disease Therapeutics Market, by Disease Severity
12.1. Introduction
12.2. Mild
12.3. Moderate
12.4. Severe
13. Crohn's Disease Therapeutics Market, by Prescription Type
13.1. Introduction
13.2. Over-The-Counter (OTC)
13.3. Prescription Drugs
14. Crohn's Disease Therapeutics Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacies
14.3. Online Pharmacies
14.4. Retail Pharmacies
15. Crohn's Disease Therapeutics Market, by Research and Development
15.1. Introduction
15.2. Biological Studies
15.2.1. Clinical Trials
15.2.2. Preclinical Trials
15.3. Chemical Synthesis
15.4. Drug Repurposing
16. Crohn's Disease Therapeutics Market, by Patient Demographics
16.1. Introduction
16.2. Gender
16.3. Lifestyle Factors
16.4. Socioeconomic Status
17. Crohn's Disease Therapeutics Market, by End User
17.1. Introduction
17.2. Academic and Research Institutions
17.3. Emergency Services
17.4. Specialty Clinics
18. Crohn's Disease Therapeutics Market, by Treatment Stage
18.1. Introduction
18.2. Initial Therapy
18.3. Maintenance Therapy
19. Crohn's Disease Therapeutics Market, by Technology Adoption Level
19.1. Introduction
19.2. High Innovation
19.3. Low Innovation
19.4. Moderate Innovation
20. Americas Crohn's Disease Therapeutics Market
20.1. Introduction
20.2. Argentina
20.3. Brazil
20.4. Canada
20.5. Mexico
20.6. United States
21. Asia-Pacific Crohn's Disease Therapeutics Market
21.1. Introduction
21.2. Australia
21.3. China
21.4. India
21.5. Indonesia
21.6. Japan
21.7. Malaysia
21.8. Philippines
21.9. Singapore
21.10. South Korea
21.11. Taiwan
21.12. Thailand
21.13. Vietnam
22. Europe, Middle East & Africa Crohn's Disease Therapeutics Market
22.1. Introduction
22.2. Denmark
22.3. Egypt
22.4. Finland
22.5. France
22.6. Germany
22.7. Israel
22.8. Italy
22.9. Netherlands
22.10. Nigeria
22.11. Norway
22.12. Poland
22.13. Qatar
22.14. Russia
22.15. Saudi Arabia
22.16. South Africa
22.17. Spain
22.18. Sweden
22.19. Switzerland
22.20. Turkey
22.21. United Arab Emirates
22.22. United Kingdom
23. Competitive Landscape
23.1. Market Share Analysis, 2024
23.2. FPNV Positioning Matrix, 2024
23.3. Competitive Analysis
23.3.1. AbbVie Inc.
23.3.2. Amgen Inc.
23.3.3. Biogen Inc.
23.3.4. Bristol-Myers Squibb Company
23.3.5. Celgene Corporation
23.3.6. Eli Lilly and Company
23.3.7. Ferring Pharmaceuticals Inc.
23.3.8. Gilead Sciences Inc.
23.3.9. Ipsen Biopharmaceuticals, Inc.
23.3.10. Johnson & Johnson
23.3.11. Merck & Co., Inc.
23.3.12. Nestlé Health Science
23.3.13. Novartis AG
23.3.14. Pfizer Inc.
23.3.15. Roche Holding AG
23.3.16. Sanofi S.A.
23.3.17. Shire plc.
23.3.18. Takeda Pharmaceutical Company Limited
23.3.19. Teva Pharmaceutical Industries Ltd.
23.3.20. UCB S.A.
24. ResearchAI
25. ResearchStatistics
26. ResearchContacts
27. ResearchArticles
28. Appendix
List of Figures
FIGURE 1. CROHN'S DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. CROHN'S DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. CROHN'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
FIGURE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2024 VS 2030 (%)
FIGURE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 34. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 38. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 39. CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 40. CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CROHN'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRECLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG REPURPOSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY LIFESTYLE FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SOCIOECONOMIC STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY EMERGENCY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INITIAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HIGH INNOVATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY LOW INNOVATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE INNOVATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 108. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 109. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 110. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 112. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 115. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 116. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 118. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 119. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 120. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 122. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 123. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 127. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 129. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 130. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 133. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 134. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 185. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 186. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 187. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 189. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 190. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 191. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 192. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 193. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 195. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 196. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 197. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 199. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 200. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 201. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 202. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 204. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 205. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 207. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 208. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 210. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 211. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 212. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 214. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 230. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 231. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 232. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 234. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 235. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 237. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 238. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 240. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 241. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 242. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 244. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 247. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 249. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 267. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 268. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 277. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 279. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 280. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 282. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 283. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 285. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 286. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 287. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 289. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE 290. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 291. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 292. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 294. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 295. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 296. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 297. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 298. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 300. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICAL STUDIES, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY ADOPTION LEVEL, 2018-2030 (USD MILLION)
TABLE

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Ferring Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Nestlé Health Science
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Shire plc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Crohn's Disease - Pipeline Insight, 2025 - Product Image

Crohn's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Crohns Disease - Pipeline Insight, 2025 - Product Image

Crohns Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • 100 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market by Type, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Inflammatory Bowel Disease Treatment Market by Type, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From

About the Crohn Disease Drug Market

Crohn Disease is a chronic inflammatory disorder of the gastrointestinal tract, and is one of the most common immune disorders. Treatment for Crohn Disease typically involves a combination of medications, lifestyle changes, and in some cases, surgery. Common medications used to treat Crohn Disease include corticosteroids, immunomodulators, biologic therapies, and antibiotics. Corticosteroids are used to reduce inflammation, while immunomodulators are used to suppress the immune system. Biologic therapies are used to target specific proteins in the body that are involved in the inflammatory process, and antibiotics are used to treat bacterial infections. The Crohn Disease Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of Crohn Disease, as well as the development of new and innovative treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.